. Author manuscript; available in PMC: 2023 Jan 1.

Published in final edited form as: Osteoporos Int. 2021 Aug 12;33(1):239–250. doi: 10.1007/s00198-021-06065-4

Table 2:

Analysis of Healing by CT at 3 months- Intention to Treat

	Teriparatide (n=18)	Placebo (n=15)	OR 95%CI for TPTD vs PBO	p-value

Bridging Score N (%) (% using mean of fractures/person)
0	1 (5.6%)	3 (20%)
1	4 (22.2%)	2 (13.3%)
2	4 (22.2%)	2 (13.3%)
3	6 (33.3%)	2 (13.3%)
4	3 (16.7%)	6 (40%)		0.72^#

Union- N (%)	9 (50%)	8 (53%)	0.88 (0.22–3.5)	0.85^*

Jonckheere-Terpstra, results were unchanged after adjusting for age, presence of a sacral fracture or displaced fracture.

results were unchanged after adjusting for age, presence of a sacral fracture or displaced fracture.